Simulations Plus sells biosimulation software, principally GastroPlus and the Pro-ZETA and ADMET Predictor platforms, which pharmaceutical companies use to model drug absorption and toxicity before running costly trials, and it earns recurring license and maintenance revenue from that base. The moat is switching cost: once a regulatory submission or internal model is built around its tools, sponsors rarely move, which supports a 63.4% gross margin and a 22.8% operating margin. Revenue growth of 7.5% is modest for a software name, so the thesis rests on margin durability and adoption of its newer AI-driven modeling products rather than on top-line acceleration. At a trailing P/E of 46.3 and a forward P/E of 52.9, the market is paying for growth the current numbers do not yet show, and a 6.2% ROE leaves little room for error. The stock merits a deeper look to test whether bookings and pharma R&D budgets can re-accelerate growth into that multiple.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 21 Oct 2026, 13:04 CEST | Fair value | $16.25 | $14.86 | $18.50 |
| 21 Oct 2026, 13:04 CEST | Rating | Overvalued | first publication | $18.50 |
| 17 Oct 2026, 00:00 CEST | Fair value | $14.86 | $14.68 | $18.50 |
| 15 Oct 2026, 00:00 CEST | ACCE price target | $16.10 | first publication | $18.50 |
| 8 Oct 2026, 00:00 CEST | Fair value | $14.68 | $14.48 | $18.50 |
| 29 Sept 2026, 00:00 CEST | Fair value | $14.48 | $14.91 | $18.46 |
| 14 Sept 2026, 00:00 CEST | Fair value | $14.91 | $15.12 | $18.42 |
| 12 Sept 2026, 00:00 CEST | Fair value | $15.12 | $15.30 | $18.42 |
| 9 Sept 2026, 00:00 CEST | Fair value | $15.30 | $15.97 | $18.43 |
| 7 Sept 2026, 00:00 CEST | Fair value | $15.97 | $15.33 | $18.43 |
Answered from Simulations Plus Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus Inc. Common Stock | $18.50 | $16 | 14% above | 46.3x | 6.2% | 75 | 64 |
| CTEV Claritev Corporation Class A Common Stock | $23.50 | - | - | - | -646.3% | 38 | 43 |
| CARL Carlsmed Inc. Common Stock | $14.53 | - | - | - | -66.1% | 47 | 51 |
| SUS.ST Surgical Science Sweden AB (publ) | kr 57.20 | kr 56 | 2% above | 31.4x | 2.1% | 70 | 63 |
| NRC National Research Corporation Common Stock (Delaware) | $21.93 | $10 | 128% above | 91.4x | 42.0% | 56 | 56 |
| EQS.PA Equasens Société anonyme | €29.65 | €41 | 28% below | 11.4x | 17.2% | 75 | 57 |
| EVH Evolent Health Inc Class A Common Stock | $4.80 | - | - | - | -67.0% | 21 | 48 |
Where SLP ranks against its sector peers on each metric.